Xvivo Perfusion AB (publ)

OM:XVIVO Rapport sur les actions

Capitalisation boursière : SEK 15.9b

La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !

Xvivo Perfusion Gestion

Gestion contrôle des critères 3/4

Le PDG Xvivo Perfusion's est Christoffer Rosenblad, nommé en Jan2022, a un mandat de 2.58 ans. détient directement 0.18% des actions de la société, d'une valeur de SEK 28.92M. La durée moyenne de mandat de l'équipe de direction et du conseil d'administration est respectivement 3.8 ans et 3.8 ans.

Informations clés

Christoffer Rosenblad

Directeur général

SEK 5.0m

Rémunération totale

Pourcentage du salaire du PDGn/a
Durée du mandat du directeur général2.7yrs
Propriété du PDG0.2%
Durée moyenne d'occupation des postes de direction2.2yrs
Durée moyenne du mandat des membres du conseil d'administration3.9yrs

Mises à jour récentes de la gestion

Recent updates

Is There An Opportunity With Xvivo Perfusion AB (publ)'s (STO:XVIVO) 40% Undervaluation?

Aug 03
Is There An Opportunity With Xvivo Perfusion AB (publ)'s (STO:XVIVO) 40% Undervaluation?

Xvivo Perfusion AB (publ) (STO:XVIVO) Stock Rockets 34% As Investors Are Less Pessimistic Than Expected

Apr 25
Xvivo Perfusion AB (publ) (STO:XVIVO) Stock Rockets 34% As Investors Are Less Pessimistic Than Expected

There Are Reasons To Feel Uneasy About Xvivo Perfusion's (STO:XVIVO) Returns On Capital

Apr 11
There Are Reasons To Feel Uneasy About Xvivo Perfusion's (STO:XVIVO) Returns On Capital

Need To Know: Analysts Just Made A Substantial Cut To Their Xvivo Perfusion AB (publ) (STO:XVIVO) Estimates

Feb 05
Need To Know: Analysts Just Made A Substantial Cut To Their Xvivo Perfusion AB (publ) (STO:XVIVO) Estimates

We Think That There Are Issues Underlying Xvivo Perfusion's (STO:XVIVO) Earnings

Feb 01
We Think That There Are Issues Underlying Xvivo Perfusion's (STO:XVIVO) Earnings

Earnings Beat: Xvivo Perfusion AB (publ) Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models

Jan 28
Earnings Beat: Xvivo Perfusion AB (publ) Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models

Returns On Capital At Xvivo Perfusion (STO:XVIVO) Have Stalled

Aug 24
Returns On Capital At Xvivo Perfusion (STO:XVIVO) Have Stalled

Why Xvivo Perfusion AB (publ) (STO:XVIVO) Could Be Worth Watching

Jul 17
Why Xvivo Perfusion AB (publ) (STO:XVIVO) Could Be Worth Watching

Do Xvivo Perfusion's (STO:XVIVO) Earnings Warrant Your Attention?

Jun 16
Do Xvivo Perfusion's (STO:XVIVO) Earnings Warrant Your Attention?

Xvivo Perfusion (STO:XVIVO) May Have Issues Allocating Its Capital

Apr 19
Xvivo Perfusion (STO:XVIVO) May Have Issues Allocating Its Capital

Are Investors Undervaluing Xvivo Perfusion AB (publ) (STO:XVIVO) By 21%?

Mar 23
Are Investors Undervaluing Xvivo Perfusion AB (publ) (STO:XVIVO) By 21%?

With EPS Growth And More, Xvivo Perfusion (STO:XVIVO) Makes An Interesting Case

Mar 07
With EPS Growth And More, Xvivo Perfusion (STO:XVIVO) Makes An Interesting Case

When Should You Buy Xvivo Perfusion AB (publ) (STO:XVIVO)?

Feb 13
When Should You Buy Xvivo Perfusion AB (publ) (STO:XVIVO)?

Be Wary Of Xvivo Perfusion (STO:XVIVO) And Its Returns On Capital

Dec 14
Be Wary Of Xvivo Perfusion (STO:XVIVO) And Its Returns On Capital

Is There An Opportunity With Xvivo Perfusion AB (publ)'s (STO:XVIVO) 35% Undervaluation?

Nov 17
Is There An Opportunity With Xvivo Perfusion AB (publ)'s (STO:XVIVO) 35% Undervaluation?

Xvivo Perfusion (STO:XVIVO) Might Be Having Difficulty Using Its Capital Effectively

Aug 20
Xvivo Perfusion (STO:XVIVO) Might Be Having Difficulty Using Its Capital Effectively

Statutory Profit Doesn't Reflect How Good Xvivo Perfusion's (STO:XVIVO) Earnings Are

Jul 21
Statutory Profit Doesn't Reflect How Good Xvivo Perfusion's (STO:XVIVO) Earnings Are

Be Wary Of Xvivo Perfusion (STO:XVIVO) And Its Returns On Capital

Mar 30
Be Wary Of Xvivo Perfusion (STO:XVIVO) And Its Returns On Capital

At kr258, Is Xvivo Perfusion AB (publ) (STO:XVIVO) Worth Looking At Closely?

Feb 18
At kr258, Is Xvivo Perfusion AB (publ) (STO:XVIVO) Worth Looking At Closely?

A Look At The Fair Value Of Xvivo Perfusion AB (publ) (STO:XVIVO)

Jan 30
A Look At The Fair Value Of Xvivo Perfusion AB (publ) (STO:XVIVO)

PDG

Christoffer Rosenblad (49 yo)

2.7yrs

Titularisation

SEK 5,031,000

Compensation

Mr. Christoffer Rosenblad serves as Chief Executive Officer at Xvivo Perfusion AB (publ) since November 30, 2022. He served as Deputy Chief Executive Officer and Global Business Development & Service Direc...


Équipe de direction

NomPositionTitularisationCompensationPropriété
Christoffer Rosenblad
Chief Executive Officer2.7yrsSEK 5.03m0.18%
SEK 28.1m
Kristoffer Nordstrom
Chief Financial Officer3.8yrspas de données0.0085%
SEK 1.3m
Lena Hagman
Chief Operating Officer1.8yrspas de données0.0063%
SEK 1.0m
Johan Holmstrom
Senior Vice President of Commercial EMEAless than a yearpas de données0.012%
SEK 1.9m
Ylva Vihoj
Global Human Resources Director1.7yrspas de donnéespas de données
Magnus Nilsson
Senior Advisor4.3yrsSEK 1.62mpas de données
Andreas Wallinder
Chief Medical Officer4yrspas de données0.011%
SEK 1.7m
Mark Reade
Senior Vice President of North Americaless than a yearpas de donnéespas de données

2.2yrs

Durée moyenne de l'emploi

54yo

Âge moyen

Gestion expérimentée: L'équipe de direction de XVIVO est considérée comme expérimentée (ancienneté moyenne 3.8 ans).


Membres du conseil d'administration

NomPositionTitularisationCompensationPropriété
Gosta Johannesson
Chairman of the Board11.7yrsSEK 440.00k0.015%
SEK 2.4m
Lars Henriksson
Independent Director3.9yrspas de données0.0076%
SEK 1.2m
Erik Stromqvist
Independent Director1.4yrspas de données0.18%
SEK 28.1m
Camilla Oberg
Independent Director8.3yrsSEK 130.00k0.0034%
SEK 545.1k
Lena Hoglund
Independent Director3.9yrspas de données0.0041%
SEK 658.3k
Goran Dellgren
Independent Director2.4yrspas de donnéespas de données

3.9yrs

Durée moyenne de l'emploi

63.5yo

Âge moyen

Conseil d'administration expérimenté: Les membres du conseil d'administration de XVIVO sont considérés comme expérimentés (ancienneté moyenne 3.8 ans).